彭布罗利珠单抗
医学
内科学
癌症
肿瘤科
免疫疗法
作者
Erica S. Tsang,Lillian L. Siu
出处
期刊:Cancer Cell
[Cell Press]
日期:2023-09-01
卷期号:41 (9): 1545-1547
被引量:2
标识
DOI:10.1016/j.ccell.2023.08.003
摘要
In this issue of Cancer Cell, Topp et al. analyze data from 799 patients treated with pembrolizumab beyond progression by RECIST 1.1 across six trials. Although 8.9%-24.4% of patients demonstrate a ≥30% reduction in target lesions, conversely 11%-18% of patients had a ≥20% increase. The benefits of treatment beyond progression must be carefully weighed against physical and financial toxicities.
科研通智能强力驱动
Strongly Powered by AbleSci AI